Shares of Stemline Therapeutics, Inc. (NASDAQ:STML) have been given an average rating of “Buy” by the nine ratings firms that are presently covering the firm, MarketBeat.com reports. Two investment analysts have rated the stock with a sell recommendation and seven have issued a buy recommendation on the company. The average 1-year price objective among brokerages that have covered the stock in the last year is $32.60.

A number of brokerages recently issued reports on STML. Zacks Investment Research downgraded Stemline Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, July 18th. BidaskClub raised Stemline Therapeutics from a “hold” rating to a “buy” rating in a report on Wednesday, July 19th. HC Wainwright reissued a “buy” rating and issued a $34.00 price objective on shares of Stemline Therapeutics in a report on Tuesday, September 12th. Jefferies Group LLC reissued a “buy” rating and issued a $16.00 price objective on shares of Stemline Therapeutics in a report on Thursday, May 25th. Finally, ValuEngine downgraded Stemline Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, August 10th.

Shares of Stemline Therapeutics (NASDAQ:STML) opened at 10.35 on Friday. The company has a 50-day moving average of $8.74 and a 200-day moving average of $8.69. The firm’s market capitalization is $242.76 million. Stemline Therapeutics has a 1-year low of $5.50 and a 1-year high of $14.60.

Stemline Therapeutics (NASDAQ:STML) last announced its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.66) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.48) by ($0.18). The business had revenue of $0.30 million during the quarter, compared to analyst estimates of $0.30 million. Stemline Therapeutics had a negative net margin of 4,176.84% and a negative return on equity of 67.35%. Equities research analysts predict that Stemline Therapeutics will post ($2.56) EPS for the current fiscal year.

Several institutional investors have recently added to or reduced their stakes in the company. FMR LLC raised its stake in shares of Stemline Therapeutics by 72.1% during the first quarter. FMR LLC now owns 2,538,892 shares of the biopharmaceutical company’s stock worth $21,708,000 after purchasing an additional 1,063,457 shares during the last quarter. Eventide Asset Management LLC raised its stake in shares of Stemline Therapeutics by 27.6% during the first quarter. Eventide Asset Management LLC now owns 1,086,400 shares of the biopharmaceutical company’s stock worth $9,289,000 after purchasing an additional 235,000 shares during the last quarter. Vanguard Group Inc. raised its stake in shares of Stemline Therapeutics by 4.7% during the second quarter. Vanguard Group Inc. now owns 863,768 shares of the biopharmaceutical company’s stock worth $7,946,000 after purchasing an additional 38,615 shares during the last quarter. AXA raised its stake in shares of Stemline Therapeutics by 44.9% during the second quarter. AXA now owns 629,205 shares of the biopharmaceutical company’s stock worth $5,789,000 after purchasing an additional 195,022 shares during the last quarter. Finally, State Street Corp raised its stake in shares of Stemline Therapeutics by 11.3% during the second quarter. State Street Corp now owns 345,363 shares of the biopharmaceutical company’s stock worth $3,179,000 after purchasing an additional 35,116 shares during the last quarter. Institutional investors and hedge funds own 48.42% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This article was originally published by American Banking News and is owned by of American Banking News. If you are viewing this article on another domain, it was copied illegally and republished in violation of international trademark & copyright legislation. The original version of this article can be accessed at https://www.americanbankingnews.com/2017/09/17/stemline-therapeutics-inc-stml-receives-consensus-recommendation-of-buy-from-brokerages.html.

About Stemline Therapeutics

Stemline Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing oncology therapeutics. The Company is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R) (CD123), present on a range of hematologic cancers.

Analyst Recommendations for Stemline Therapeutics (NASDAQ:STML)

Receive News & Ratings for Stemline Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.